<DOC>
	<DOC>NCT01887418</DOC>
	<brief_summary>Relative Bioavailability and Safety comparison of 3 formulations of Testosterone Enanthate.</brief_summary>
	<brief_title>Pharmacokinetic Study of Testosterone Enanthate</brief_title>
	<detailed_description>Standard Pharmacokinetic (PK) analyses of data for serum testosterone were done. Cmax, Area Under Curve (AUC), and Cavg were used for the comparison of relative bioavailability of the treatments and reference arm. Safety comparisons were based upon the occurrence, severity and rate of treatment emergent adverse events.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Adult males aged 18 to 75 with a documented diagnosis of hypogonadism Normal testosterone levels Subjects with any clinically significant medical condition which, in the opinion of the Investigator, would make the subject an unsuitable candidate for enrollment in the study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Testosterone enanthate</keyword>
</DOC>